Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection

Background After ischemic stroke, hypertension increases the risk of recurrence, hemorrhage and fatal cerebral edema, but blood pressure (BP) lowering in the acute stroke period is controversial due to fears of infarct extension and worsened outcomes. Objective To determine whether BP lowering with candesartan, initiated at reperfusion, can reduce neurovascular damage and improve outcome in a model of hypertension after experimental ischemic stroke. Methods Male Wistar rats (280–305 g) underwent 3 h of middle cerebral artery occlusion (MCAO). At reperfusion, either saline (n = 18) or candesartan 1 mg/kg (n = 18) was administered intravenously. BP was measured by telemetry for 2 days before and 24 h after MCAO. Neurologic function was assessed and sacrifice occurred at 24 h after occlusion. Brain tissue was analyzed for infarct size, hemoglobin content and edema. Results Mean BP increased from 96 to 124 mmHg immediately upon MCAO and decreased to 114 mmHg after reperfusion, remaining elevated for 24 h (P < 0.001) in the saline group. Candesartan reduced BP back to baseline and BP remained lower than in saline-treated animals until sacrifice (P < 0.001). Infarct size (54 versus 38%, P = 0.01) and hemoglobin content (23.4 versus 10.0 μg/g tissue; P = 0.03) and edema (17.97 versus 11.33%, P < 0.0001) were lower in the candesartan group. In addition, neurologic function at 24 h was improved (P = 0.0036) in the candesartan group. Conclusions Candesartan administered after reperfusion in acute ischemic stroke reduces neurovascular damage and improves outcome.

[1]  R. Chen,et al.  Possible Inhibition of Focal Cerebral Ischemia by Angiotensin II Type 2 Receptor Stimulation , 2004, Circulation.

[2]  John H. Zhang,et al.  Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury. , 2004, American journal of physiology. Heart and circulatory physiology.

[3]  J. Leonardi-Bee,et al.  High blood pressure in acute stroke and subsequent outcome: a systematic review. , 2004, Hypertension.

[4]  M. Forsting,et al.  The Angiotensin II Type 1—Receptor Blocker Candesartan Increases Cerebral Blood Flow, Reduces Infarct Size, and Improves Neurologic Outcome after Transient Cerebral Ischemia in Rats , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  R. Knight,et al.  Single slice method for quantification of hemorrhagic transformation using direct ELISA , 2004, Neurological research.

[6]  T. Unger,et al.  Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats , 2003, Journal of hypertension.

[7]  S. Mayer,et al.  Blood pressure reduction in ischemic stroke , 2003, Neurology.

[8]  H. Diener,et al.  The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors , 2003, Stroke.

[9]  G. Mancia,et al.  International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. , 2003, Journal of hypertension.

[10]  R. Grubb,et al.  Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association , 2003, Stroke.

[11]  P. Sandercock,et al.  Blood Pressure and Clinical Outcomes in the International Stroke Trial , 2002, Stroke.

[12]  Y. Katayama,et al.  Hemorrhagic Transformation After Fibrinolysis With Tissue Plasminogen Activator: Evaluation of Role of Hypertension With Rat Thromboembolic Stroke Model , 2001, Stroke.

[13]  L. Murri,et al.  Transient autonomic nervous system dysfunction during hyperacute stroke , 2000, Acta neurologica Scandinavica.

[14]  JurajCulman,et al.  Blockade of Central Angiotensin AT1 Receptors Improves Neurological Outcome and Reduces Expression of AP-1 Transcription Factors After Focal Brain Ischemia in Rats , 1999 .

[15]  T. Herdegen,et al.  Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. , 1999, Stroke.

[16]  Á. Chamorro,et al.  Blood pressure and functional recovery in acute ischemic stroke. , 1998, Stroke.

[17]  P. Lyden,et al.  Acute Hypertension Promotes Hemorrhagic Transformation in a Rabbit Embolic Stroke Model: Effect of Labetalol , 1998, Experimental Neurology.

[18]  S. Fagan,et al.  Acute Hypertension, but Not Thrombolysis, Increases the Incidence and Severity of Hemorrhagic Transformation Following Experimental Stroke in Rabbits , 1996, Experimental Neurology.

[19]  V. Hachinski,et al.  Autonomic and myocardial changes in middle cerebral artery occlusion: stroke models in the rat , 1989, Brain Research.

[20]  K. Lamers,et al.  Blood pressure and both venous and urinary catecholamines after cerebral infarction , 1988, Clinical Neurology and Neurosurgery.

[21]  L. Pitts,et al.  Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. , 1986, Stroke.

[22]  J. Zivin,et al.  Hypertension in acute ischemic strokes. Not to treat. , 1985, Archives of neurology.

[23]  J. Spence,et al.  Hypertension in acute ischemic strokes. Treat. , 1985, Archives of neurology.

[24]  M. Giroud,et al.  Risk factors for primary cerebral hemorrhage: a population-based study--the Stroke Registry of Dijon. , 1995, Neuroepidemiology.

[25]  P. Weinstein,et al.  Reversible middle cerebral artery occlusion without craniectomy in rats. , 1989, Stroke.